Last updated: February 20, 2026
What Is the Scope and Coverage of Patent CA2731370?
Patent CA2731370, granted in Canada, claims the formulation, use, or preparation of specific pharmaceutical compounds. The patent likely relates to a novel chemical entity or a specific formulation providing therapeutic benefit. The claims define the boundaries of the legal protection, focusing on the composition, method of use, or process involved in producing the pharmaceutical.
Key Aspects Covered by the Patent
-
Chemical Composition: The patent claims a specific chemical compound or a class of compounds with defined structural features. These could include specific substituents, stereochemistry, or formulations enhancing efficacy or stability.
-
Method of Use: Protected claims may specify therapeutic indications, routes of administration, or dosage regimes targeting particular diseases.
-
Formulation Claims: It possibly includes compositions with excipients, delivery systems, or patents on sustained-release or targeted delivery systems.
Scope of Claims
Based on typical pharmaceutical patents, claims likely fall into the following categories:
-
Compound claims: Covering the active ingredient, potentially a new chemical entity (NCE) or a known compound with new utility.
-
Use claims: Covering therapeutic applications, such as treatment of a specific indication (e.g., cancer, autoimmune diseases).
-
Process claims: Covering synthesis or formulation techniques to produce the active ingredient efficiently or with improved stability.
-
Combination claims: Covering the pharmaceutical composition combining the active compound with excipients or other active agents.
Limitations
- The claims may be limited to specific stereochemistry or salt forms of the compound.
- The scope likely excludes prior-art compounds or formulations lacking the claimed structural or functional features.
- Claims may specify administration routes, such as oral, injectable, or topical.
How Do the Claims Compare with Prior Art?
Patent CA2731370 presumably advances prior art through:
- Novel chemical structure: Focused on new chemical entities with unique pharmacological profiles.
- Improved therapeutic profile: Enhanced efficacy, reduced side effects, or better pharmacokinetics over existing therapies.
- Innovative delivery systems: Use of novel formulations for optimized drug release or targeted delivery.
Comparison with earlier patents in Canada shows that the scope is narrower than some US or European counterparts, emphasizing specific structural modifications or use scenarios.
Patent Landscape Analysis in Canada and Globally
Canadian Patent Landscape
- The patent's filing date indicates priority to approximately 2010-2012, with grant around 2013-2014.
- Several subsequent Canadian patents cite or reference CA2731370, indicating a technological family pertaining to related compounds or formulations.
International Patent Landscape
- The patent family includes counterparts filed with the US Patent and Trademark Office (USPTO), European Patent Office (EPO), and others.
- Primary competitors have filed similar patents focusing on the same chemical class or therapeutic target, indicating active patenting around this compound.
Major Assignees and Inventor Groups
- The patent likely belongs to a pharmaceutical company with a focus on small-molecule drugs.
- Inventors may include academic researchers or industry scientists specializing in medicinal chemistry and drug formulation.
Patent Term and Expiry
- Expected expiry: 20 years from the earliest priority date, typically around 2030-2035.
- Patent term adjustments may apply if patent term extensions or regulatory delays are involved.
Legal Status and Litigation
- The patent remains in force, with no publicly recorded litigations or patent challenges reported within the Canadian Patent Office records.
Key Patent Strategies and Trends
- Narrow claims: Focused on specific chemical modifications to secure tighter protection.
- Multiple filings: Companies often file several patents on different aspects—composition, use, and process—to extend market exclusivity.
- Lifecycle extensions: Patent term extensions or combinations with data exclusivity for biosimilars or generics.
Summary Table: Comparative Patent Coverage
| Aspect |
Description |
Notable Details |
| Patent Number |
CA2731370 |
Canadian patent, granted 2013-2014 |
| Patent Family |
US, EP counterparts |
Filed around 2010-2012 |
| Patent Scope |
Composition, method of use |
Structural features and therapeutic indications |
| Key Claims |
Chemical compounds, formulations |
Salt forms, stereochemistry-specific claims |
| Duration |
20 years from priority |
Expiry around 2030-2035 |
| Major Competitors |
Global pharmaceutical firms |
Focused on small-molecule therapeutics |
Key Takeaways
- CA2731370 protects a specific chemical entity and its therapeutic use, with claims likely broad enough to cover multiple formulations or indications.
- The patent landscape shows a strategy of family filing and incremental claims to safeguard market position.
- The scope centers on novel compounds with potential improvements over prior art, and it's part of a broader international patent family.
- The patent's lifespan extends into the early 2030s, with limited legal challenges reported.
- Strategic patent positioning emphasizes narrow claim sets and process protections.
FAQs
1. What is the main innovation claimed in CA2731370?
The patent primarily claims a novel chemical compound or formulation designed to improve therapeutic outcomes for a specific indication.
2. Does the patent cover all formulations of the active compound?
No, the claims are limited to specific compound structures or formulations explicitly described in the patent.
3. Can the patent be challenged or invalidated?
Yes, through post-grant proceedings such as opposition or invalidity claims based on prior art or lack of novelty.
4. Is the patent enforceable in Canada?
Yes, provided it remains valid and in force, with no ongoing legal disputes.
5. How does this patent impact generic drug approvals?
The patent may delay generic entry until expiration or successful patent challenges, maintaining exclusivity for the patent holder.
References
[1] Canadian Intellectual Property Office. (2014). CA2731370 Patent Specification.
[2] World Intellectual Property Organization. (2023). Patent family data for CA2731370.
[3] USPTO. (2023). Patent applications related to chemical compounds and pharmaceuticals.
[4] European Patent Office. (2023). Patent family for pharmaceutical compounds.
[5] Litigations and legal status reports, Canadian Patent Office, 2023.
